血清CXCL5作为多发性硬化症和视神经脊髓炎谱系障碍的生物标志物。
Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder.
作者信息
Karaaslan Zerrin, Yilmaz Vuslat, Yuceer Hande, Sanli Elif, Akcay Halil Ibrahim, Kurtuncu Murat, Turkoglu Recai, Tuzun Erdem
机构信息
Department of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
Department of Neurology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye.
出版信息
North Clin Istanb. 2023 Jun 19;10(3):341-344. doi: 10.14744/nci.2022.77861. eCollection 2023.
OBJECTIVE
Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response.
METHODS
CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls.
RESULTS
Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients.
CONCLUSION
Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.
目的
我们的目的是确定血清C-X-C基序趋化因子5（CXCL5）是否可作为复发缓解型多发性硬化症（RRMS）的诊断生物标志物以及可用于预测治疗反应的标志物。
方法
采用酶联免疫吸附测定法（ELISA）检测20例接受芬戈莫德治疗的RRMS患者、10例视神经脊髓炎谱系障碍（NMOSD）患者、15例主要表现为脊髓和视神经发作的RRMS患者（MS-SCON）以及14名健康对照者血清中的CXCL5水平。
结果
芬戈莫德治疗显著降低了CXCL5水平。NMOSD和MS-SCON患者的CXCL5水平相当。
结论
芬戈莫德可能调节先天性免疫系统。血清CXCL5检测无法区分RRMS和NMOSD。
Zotero 插件